Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory or Recurrent Hypermutated Malignancies”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Testing effectiveness (Phase 2)Ended earlyNCT02992964
What this trial is testing

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Who this might be right for
Refractory or Recurrent Hypermutated MalignanciesBiallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
The Hospital for Sick Children 11
Early research (Phase 1)Active Not RecruitingNCT02359565
What this trial is testing

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeLynch SyndromeMalignant Glioma+8 more
National Cancer Institute (NCI) 71